Safety and efficacy of nilotinib in adult patients with chronic myeloid leukemia: a post-marketing surveillance study in Korea
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Ahn, S.-Y. | - |
dc.contributor.author | Son, S.K. | - |
dc.contributor.author | Lee, G.H. | - |
dc.contributor.author | Kim, I. | - |
dc.contributor.author | Cheong, J.-W. | - |
dc.contributor.author | Lee, W.S. | - |
dc.contributor.author | Kim, B.S. | - |
dc.contributor.author | Jo, D.-Y. | - |
dc.contributor.author | Jung, C.W. | - |
dc.contributor.author | Seong, C.M. | - |
dc.contributor.author | Lee, J.H. | - |
dc.contributor.author | Yuh, Y.J. | - |
dc.contributor.author | Kim, M.K. | - |
dc.contributor.author | Ryoo, H.-M. | - |
dc.contributor.author | Park, M.-R. | - |
dc.contributor.author | Cho, S.-H. | - |
dc.contributor.author | Kim, H.-G. | - |
dc.contributor.author | Zang, D.Y. | - |
dc.contributor.author | Park, J. | - |
dc.contributor.author | Kim, H. | - |
dc.contributor.author | Lee, S. | - |
dc.contributor.author | Kim, S.-H. | - |
dc.contributor.author | Chang, M.H. | - |
dc.contributor.author | Lee, H.S. | - |
dc.contributor.author | Choi, C.W. | - |
dc.contributor.author | Kwon, J. | - |
dc.contributor.author | Lim, S.-N. | - |
dc.contributor.author | Oh, S.-J. | - |
dc.contributor.author | Joo, I. | - |
dc.contributor.author | Kim, D.-W. | - |
dc.date.accessioned | 2022-11-20T01:40:18Z | - |
dc.date.available | 2022-11-20T01:40:18Z | - |
dc.date.created | 2022-11-18 | - |
dc.date.issued | 2022 | - |
dc.identifier.issn | 2287-979X | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/146050 | - |
dc.description.abstract | Background Nilotinib is a tyrosine kinase inhibitor approved by the Ministry of Food and Drug Safety for frontline and 2nd line treatment of Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML). This study aimed to confirm the safety and efficacy of nilotinib in routine clinical practice within South Korea. Methods An open-label, multicenter, single-arm, 12-week observational post-marketing surveillance (PMS) study was conducted on 669 Korean adult patients with Ph+ CML from December 24, 2010, to December 23, 2016. The patients received nilotinib treatment in routine clinical practice settings. Safety was evaluated by all types of adverse events (AEs) during the study period, and efficacy was evaluated by the complete hematological response (CHR) and cytogenetic response. Results During the study period, AEs occurred in 61.3% (410 patients, 973 events), adverse drug reactions (ADRs) in 40.5% (271/669 patients, 559 events), serious AEs in 4.5% (30 patients, 37 events), and serious ADRs in 0.7% (5 patients, 8 events). Furthermore, unexpected AEs occurred at a rate of 6.9% (46 patients, 55 events) and unexpected ADRs at 1.2% (8 patients, 8 events). As for the efficacy results, CHR was achieved in 89.5% (442/494 patients), and minor cytogenetic response or major cytogenetic response was achieved in 85.8% (139/162 patients). Conclusion This PMS study shows consistent results in terms of safety and efficacy compared with previous studies. Nilotinib was well tolerated and efficacious in adult Korean patients with Ph+ CML in routine clinical practice settings. © 2022 Korean Society of Hematology. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | Korean Society of Hematology | - |
dc.title | Safety and efficacy of nilotinib in adult patients with chronic myeloid leukemia: a post-marketing surveillance study in Korea | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Choi, C.W. | - |
dc.identifier.doi | 10.5045/br.2022.2021137 | - |
dc.identifier.scopusid | 2-s2.0-85133544724 | - |
dc.identifier.bibliographicCitation | Blood Research, v.57, no.2, pp.144 - 151 | - |
dc.relation.isPartOf | Blood Research | - |
dc.citation.title | Blood Research | - |
dc.citation.volume | 57 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 144 | - |
dc.citation.endPage | 151 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.identifier.kciid | ART002849619 | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.subject.keywordAuthor | Chronic myeloid leukemia | - |
dc.subject.keywordAuthor | Nilotinib | - |
dc.subject.keywordAuthor | Philadelphia chromosome positive | - |
dc.subject.keywordAuthor | Post-marketing surveillance | - |
dc.subject.keywordAuthor | Tyrosine kinase inhibitor | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.